CAMBRIDGE–Neurotechnology company Axoft has reported new clinical findings from human and animal studies of its ultra-soft Fleuron brain-computer interface (BCI) probes, highlighting progress in recording neural activity and developing technology to assess consciousness in patients with severe neurological conditions.
The findings come from ongoing research at Mass General Brigham and The Panama Clinic, where the company’s implantable probes have demonstrated stable neural recordings and the ability to detect changes in brain activity associated with different states of consciousness.
Axoft’s technology uses its proprietary Fleuron material, designed to move with the brain and minimize tissue disruption while collecting high-resolution neural data. The company is developing the technology to help physicians better evaluate patients who are in comas, vegetative states or minimally conscious states.
“Every year in the U.S., traumatic brain injuries lead to 2.9 million emergency room visits, with many patients ending up in an unresponsive state. Physicians will look for signs of consciousness by prompting a response, but consciousness and the ability to respond are not the same,” said Dr. Paul Le Floch, Co-Founder and CEO of Axoft.
The company reported several findings from its latest clinical research.
At The Panama Clinic, five patients received temporary implants of Axoft’s Fleuron probes in the brain’s cortex during procedures. Researchers collected neural data from four patients, including two who were awake and two who were asleep. The information was then used to demonstrate real-time classification of the anesthetic state in a fifth patient without requiring additional patient-specific training.
The findings, which represent an early demonstration of the technology’s potential to identify different states of consciousness, were presented by Axoft researcher Jordy Tasserie, PhD, at the Neurocritical Care Society’s annual meeting in Seattle in October.
In another study involving seven patients at Mass General Brigham and The Panama Clinic, Fleuron probes were implanted during planned surgeries to remove brain tumors or hematomas.
The company reported that the probes produced stable neural recordings, with up to 85% of recording channels capturing signals characterized by single-unit spike signal-to-noise measurements.
Jessica Grossman, MD, presented additional findings at the 76th Annual Congress of Neurological Surgeons, held from October 31 through November 4 in Washington, D.C.
Researchers also examined data collected from pigs and humans at Mass General Brigham to evaluate how the probes respond to natural brain movement.
The findings indicated that the flexible probes moved with the brain, reducing the movement of recording electrodes relative to individual neurons caused by brain pulsations. According to Axoft, this helped maintain stable neural recordings without requiring additional adjustments to compensate for electrode movement.
Jake Swann, PhD, of Axoft and Angelique Paulk, PhD, of Mass General Brigham presented the research at the Society for Neuroscience meeting in Washington, D.C., held November 14-18.
The company believes these findings could support the development of more reliable tools for assessing neurological function in patients who cannot communicate through conventional means.
“Axoft is measuring consciousness directly from the brain to provide a much-needed voice to the almost half (43%) of neuro-ICU patients who are misdiagnosed when it comes to their state of consciousness. This clinical momentum demonstrates our progress in safely collecting vital neural data to transform how patients who are in comas, vegetative states or minimally conscious states are assessed and treated, with long-term applications potentially extending into treatments for epilepsy, movement disorders and other neurological conditions,” Le Floch said.
The research remains at an early stage, with the reported human findings focused on neural signal recording and the feasibility of distinguishing different brain states.
The latest results follow a $55 million Series A financing round completed by Axoft in April to support the advancement of clinical trials.
The company has also received industry recognition in 2026, including a MedTech Breakthrough Award, selection as a finalist for the MedTech Innovator Mid-Stage Grand Prize and inclusion on Fast Company’s Next Big Things in Tech list.
In August, Axoft expanded its advanced polymer portfolio with Fleuron Water Invisible Soft Elastomer (WISE), a UV-curable material designed to match water’s refractive index when submerged. The material is intended to support high-resolution imaging of biological samples and living organisms.
Axoft also recently added Alex Zhavoronkov, Founder and CEO of Insilico Medicine, as an angel investor.
The company is continuing to develop its brain-computer interface technology for potential applications in neurological assessment and treatment, including epilepsy and movement disorders.


